Harmony Biosciences(HRMY)
Focus: Harmony Biosciences is a public biotech company focused on sleep and CNS disorders, generating $582M in FY2025 revenue primarily from its flagship narcolepsy treatment WAKIX. The company operates as a specialized player in neurology with a diversifying pipeline across rare neurological conditions.
Profile data last refreshed 17h ago · AI intelligence enriched 1w ago
Funding Stage
PUBLIC
Open Jobs
4
Should You Work at Harmony Biosciences?
AI assessmentSuitable for specialists seeking near-term stability and CNS disease expertise, but risky for those seeking long-term career growth or diverse project exposure.
Why Work Here
- Strong profitability with $129M net income on $582M revenue (FY2025), providing stable funding for R&D and career development
- Expanding pipeline with multiple Phase 3 programs (Pitolisant for Prader-Willi, Idiopathic Hypersomnia; Clemizole for Dravet and Lennox-Gastaut) offering visibility into near-term catalysts
Data completeness
6/9 — Partial
Company HealthStrong
Pipeline
Late-stage
8 Phase 3+
LOE Risk
1 in 5yr
WAKIX
Hiring
Growing
Jobs increasing
Revenue
Key Products
$101M Part DStable
Peak3.3yr
Help build intelligence for Harmony Biosciences
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.